Dear god, I come up for air after a week of manuscript and dissertation writing to find
37 pages of comments on the Naviaux article between this thread and
other one.
After a couple hours of digesting all this, here's where I'm at regarding the article results:
1) Hooray for a PNAS article using cutting edge methods to do new basic research on ME/CFS patient samples! Congratulations to all of the researchers working hard on this. Also thanks to those involved outreach and keeping everyone in the loop regarding additional info on these forums, such as
@Ben Howell @JaimeS and
@Rose49.
2) 40 metabolites of the 600+ tested are outside of normal values (did I read 2-sigma outside, or am I making stuff up?) for the ME/CFS cohort, as compared to an average of 16 for controls. These abnormal metabolite levels are predominantly lower than average, indicating a hypometabolic phenotype. Note that this patient population is textbook definition chronic, with average duration of illness around 20 years.
3) Pathway analysis shows 5 independent irregularities for male, six for female, and nine shared. The pathways involved are primarily forms of lipid metabolism (sphingolipid, glycosphingolipid, phospholipid and cholesterol metabolic pathways). Other key results involve low levels of FAD (M + F), purines (M + F), and vitamin B12 (Female only).
4) Interestingly, while these pathways are involved in metabolic syndrome and acute cell danger response, the metabolites are regulated in the opposite direction in the ME/CFS cohort. A similar profile is seen in the dauer metabolic state in model organism
C. elegans, where larvae trade off cell replication and sexual maturation in favor of increased hardiness in response to environmental stress.
5) The hypometabolic pathways in ME/CFS are affected by redox state and NADPH availability in the cell, and are thus indicative of low cell energy reserves.
6) This altered homeostasis reflecting a hypometabolic state is consistent regardless of initial onset, and greater deviation from the norm (more metabolites outside of norm/values further from the mean for individual metabolites) correlates with increased symptom severity.
7) Independent replication of these results using the Metabolon system are being hotly pursued as both a baseline for future hypothesis driven research, and as a diagnostic for the disease.
Here are a few of my questions and musings for what they're worth:
1) A lot of the subsequent discussion has revolved around what this research might suggest in terms of treatment and supplementation. If, as this research suggests, an altered homeostasis exists, then supplementation may have transient value as cells try to return to their new homeostatic norm, as
@alex3619 has pointed out. It may, however, help suggest why people have had some limited symptom improvement with vitamin B injections (low B12 in females). It will be interesting to see if the OMF B12 trial sees a greater symptom improvement in women vs. men.
2) Great point about the ME/CFS cohort supplementing with DHA/Omega-3's, since it's part of the only consistently increased phospholipid - PC(18:1/22:6). I wonder if that info could be captured for a post-hoc analysis with a questionnaire to the participants.
3) I don't have a good handle at all on how dependent synthesis of these lipid metabolites is on their intake. Their synthesis dependency on NADPH and FAD is discussed in the paper, but it's possible that increasing dietary supply of their precursors would have some value as a novel target (though see caveat of musing #1). For example, digestive enzyme supplementation with amylase or lipase to improve dietary uptake of lipids could improve some of these values. Let's let that get tested in the lab first though, yeah?
4) I'm a little unclear regarding the plasma preparation phase for analysis, which is described in
another paper. It looks like there's a single extraction step for all of the metabolites tested, with 4 volumes of acetonitrile:methanol (50:50) per volume of plasma containing controls and standards. Is that correct? I'm hoping that's the case, rather than requiring additional drying and enrichment steps for the lipids, since that helps with designing a diagnostic screen.
5) Is there a murine (mouse) model in literature which demonstrates dauer-like metabolic characteristics? If so, this metabolic pattern might be something to look for as researchers attempt to develop and validate an animal model of ME/CFS.
6) This one is
way out there folks. Just to drag this back to self-management of disease, assume we see independent replication and confirmation of these results, with correlation of disease severity to a subset of around 10 metabolites. We're starting to see initiatives like
Cor starting to pop up, where regular home blood monitoring can be linked by apps and aggregated in the cloud using advanced data analytics. The idea is that you start a regimen (supplement, exercise, etc), combine it with important daily subjective outputs (pain, energy level, was I able to clean the house?) see how it affects your day to day blood values, and come up with something that works for you. Right now these systems are being developed to monitor basic values like blood glucose, cholesterol, LDL, HDL and fibrinogen. It wouldn't be surprising to see variants for specific diseases following on in the next 5 - 10 years though. Then we could really make progress on some of these treatment questions we've been asking
Apologies for the
massive post. Common side effects of dissertation writing include verbal diarrhea and wild hypotheses on future research directions.